Oruka Therapeutics, Inc. Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs
Oruka Therapeutics, Inc. (ORKA) reported Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs of $20.50 million for the 11-month period ending 2024-12-31, per its 10-K filed 2026-03-12.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts · last filed 2026-03-12
- Oruka Therapeutics, Inc. adjustments to additional paid in capital, stock issued, issuance costs for the quarter ending 2024-09-30 was $20.48M.
| Period end | Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs 3 month | Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs 11 month | Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs 12 month | Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs 12 month as first filed |
|---|---|---|---|---|
| 2024-12-31 | $20.50M 10-K · filed 2026-03-12 | |||
| 2024-09-30 | $20.48M 10-Q · filed 2025-11-12 | |||
| 2006-12-31 | -$17.00K 10-Q · filed 2013-08-13 | $17.00K 10-K · filed 2013-03-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Veradermics, Inc (MANE) | United States | $4.839B |